EP0137794A1 - Clavam derivatives - Google Patents
Clavam derivativesInfo
- Publication number
- EP0137794A1 EP0137794A1 EP84900634A EP84900634A EP0137794A1 EP 0137794 A1 EP0137794 A1 EP 0137794A1 EP 84900634 A EP84900634 A EP 84900634A EP 84900634 A EP84900634 A EP 84900634A EP 0137794 A1 EP0137794 A1 EP 0137794A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- clavam
- benzyl
- carboxylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WSHJJCPTKWSMRR-RXMQYKEDSA-N penam Chemical class S1CCN2C(=O)C[C@H]21 WSHJJCPTKWSMRR-RXMQYKEDSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 139
- -1 hydroxy, substituted hydroxy, mercapto, substituted mercapto Chemical group 0.000 claims abstract description 81
- 150000002148 esters Chemical class 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 125000003118 aryl group Chemical group 0.000 claims abstract description 25
- 239000001257 hydrogen Substances 0.000 claims abstract description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000012038 nucleophile Substances 0.000 claims abstract description 10
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims abstract description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 229930182555 Penicillin Natural products 0.000 claims description 18
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229940049954 penicillin Drugs 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000001425 triazolyl group Chemical group 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000005418 aryl aryl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
- 229910004727 OSO3H Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 11
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 137
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 104
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 88
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 87
- 239000000203 mixture Substances 0.000 description 81
- 239000000243 solution Substances 0.000 description 79
- 238000006243 chemical reaction Methods 0.000 description 70
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- 229940093499 ethyl acetate Drugs 0.000 description 46
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 46
- 235000019439 ethyl acetate Nutrition 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 229910001868 water Inorganic materials 0.000 description 42
- 239000003921 oil Substances 0.000 description 40
- 239000000047 product Substances 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 35
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- 229960001866 silicon dioxide Drugs 0.000 description 29
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 28
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 26
- 239000002904 solvent Substances 0.000 description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 18
- 239000003054 catalyst Substances 0.000 description 18
- 229910052744 lithium Inorganic materials 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 17
- 239000003480 eluent Substances 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000006722 reduction reaction Methods 0.000 description 15
- 150000003952 β-lactams Chemical class 0.000 description 14
- 229930186147 Cephalosporin Natural products 0.000 description 13
- 229940124587 cephalosporin Drugs 0.000 description 13
- 150000001780 cephalosporins Chemical class 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 125000002252 acyl group Chemical group 0.000 description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 10
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 10
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 10
- 150000002430 hydrocarbons Chemical group 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- 125000004423 acyloxy group Chemical group 0.000 description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 238000005917 acylation reaction Methods 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- 229960003022 amoxicillin Drugs 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 125000001246 bromo group Chemical group Br* 0.000 description 8
- 239000003610 charcoal Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 8
- 150000002960 penicillins Chemical class 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 230000000994 depressogenic effect Effects 0.000 description 7
- 229960004132 diethyl ether Drugs 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 125000005236 alkanoylamino group Chemical group 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 6
- 229960004659 ticarcillin Drugs 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 5
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 150000001540 azides Chemical class 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 5
- 229960003669 carbenicillin Drugs 0.000 description 5
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 5
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 5
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 125000002346 iodo group Chemical group I* 0.000 description 5
- 229910003002 lithium salt Inorganic materials 0.000 description 5
- 159000000002 lithium salts Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 150000003335 secondary amines Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- CQCAYWAIRTVXIY-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetaldehyde Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC=O)C1=CC=CC=C1 CQCAYWAIRTVXIY-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 102000006635 beta-lactamase Human genes 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 125000005633 phthalidyl group Chemical group 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108020004256 Beta-lactamase Proteins 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 description 3
- AZUFHGGGPUUXKI-FLFDDASRSA-N benzyl (2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound O=C([C@@H]1N2C(=O)C[C@H]2O\C1=C/CO)OCC1=CC=CC=C1 AZUFHGGGPUUXKI-FLFDDASRSA-N 0.000 description 3
- 239000000460 chlorine Chemical group 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 3
- 229960003324 clavulanic acid Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- TXWFLGWLNVQIEX-UHFFFAOYSA-N cyclohexane;ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O.C1CCCCC1 TXWFLGWLNVQIEX-UHFFFAOYSA-N 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000003949 imides Chemical class 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000786363 Rhampholeon spectrum Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229910000091 aluminium hydride Inorganic materials 0.000 description 2
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229960003311 ampicillin trihydrate Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 2
- 229960003866 cefaloridine Drugs 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- MZMJHXFYLRTLQX-UHFFFAOYSA-N ethenylsulfinylbenzene Chemical compound C=CS(=O)C1=CC=CC=C1 MZMJHXFYLRTLQX-UHFFFAOYSA-N 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 2
- JXMLAPZRDDWRRV-UHFFFAOYSA-N ethyl n-(ethoxycarbonylamino)carbamate Chemical compound CCOC(=O)NNC(=O)OCC JXMLAPZRDDWRRV-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 2
- 229960003884 hetacillin Drugs 0.000 description 2
- 150000002390 heteroarenes Chemical class 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000005949 ozonolysis reaction Methods 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 238000005055 short column chromatography Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000011182 sodium carbonates Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HRTKQUHFGZFPPF-UHFFFAOYSA-M tetraethylazanium;fluoride;dihydrate Chemical compound O.O.[F-].CC[N+](CC)(CC)CC HRTKQUHFGZFPPF-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- YKPQUSLRUFLVDA-UHFFFAOYSA-N $l^{2}-azanylmethane Chemical compound [NH]C YKPQUSLRUFLVDA-UHFFFAOYSA-N 0.000 description 1
- JETQIUPBHQNHNZ-NJBDSQKTSA-N (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)S(O)(=O)=O)=CC=CC=C1 JETQIUPBHQNHNZ-NJBDSQKTSA-N 0.000 description 1
- WRFCGBVLTRJBKN-QSNWEANLSA-N (2s,5r,6r)-6-[[(2r)-2-[[2-[[amino(pyridin-4-yl)methylidene]amino]acetyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)CN=C(N)C1=CC=NC=C1 WRFCGBVLTRJBKN-QSNWEANLSA-N 0.000 description 1
- SBUCDZYLTRYMFG-PBFPGSCMSA-N (6r,7r)-7-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](N)C=3C=CC(O)=CC=3)[C@H]2SC1 SBUCDZYLTRYMFG-PBFPGSCMSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SSUJUUNLZQVZMO-UHFFFAOYSA-N 1,2,3,4,8,9,10,10a-octahydropyrimido[1,2-a]azepine Chemical compound C1CCC=CN2CCCNC21 SSUJUUNLZQVZMO-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- KAANTNXREIRLCT-UHFFFAOYSA-N 1-(triphenyl-$l^{5}-phosphanylidene)propan-2-one Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)C)C1=CC=CC=C1 KAANTNXREIRLCT-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- SHCFCJUJGBRSPO-UHFFFAOYSA-N 1-cyclohexylcyclohexan-1-amine Chemical compound C1CCCCC1C1(N)CCCCC1 SHCFCJUJGBRSPO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SCAKFUJVCFIFOX-UHFFFAOYSA-N 1-phenylsulfanylpyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1SC1=CC=CC=C1 SCAKFUJVCFIFOX-UHFFFAOYSA-N 0.000 description 1
- NDVMCQUOSYOQMZ-UHFFFAOYSA-N 2,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)C(C(N)=O)[Si](C)(C)C NDVMCQUOSYOQMZ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 description 1
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 description 1
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000220438 Arachis Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000003547 Friedel-Crafts alkylation reaction Methods 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- VMPVEPPRYRXYNP-UHFFFAOYSA-I antimony(5+);pentachloride Chemical compound Cl[Sb](Cl)(Cl)(Cl)Cl VMPVEPPRYRXYNP-UHFFFAOYSA-I 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ODFHGIPNGIAMDK-NJBDSQKTSA-N azidocillin Chemical compound C1([C@@H](N=[N+]=[N-])C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 ODFHGIPNGIAMDK-NJBDSQKTSA-N 0.000 description 1
- 229960004328 azidocillin Drugs 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 description 1
- 229960005412 bacampicillin hydrochloride Drugs 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960003972 cefacetrile Drugs 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- ICZOIXFFVKYXOM-YCLOEFEOSA-M cefamandole nafate Chemical compound [Na+].CN1N=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)C=3C=CC=CC=3)[C@H]2SC1 ICZOIXFFVKYXOM-YCLOEFEOSA-M 0.000 description 1
- 229960002440 cefamandole nafate Drugs 0.000 description 1
- 229950000042 cefaparole Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- VIXCQEYUSKSFNN-UHFFFAOYSA-N dihydrate;hydrofluoride Chemical compound O.O.F VIXCQEYUSKSFNN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 description 1
- 229960002457 epicillin Drugs 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- GIGAVEHCPDOYLJ-UHFFFAOYSA-N ethyl acetate;propan-2-ol;hydrate Chemical compound O.CC(C)O.CCOC(C)=O GIGAVEHCPDOYLJ-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AESFJDICLJFXLK-UHFFFAOYSA-N iodomethane;triphenyl phosphite Chemical compound IC.C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 AESFJDICLJFXLK-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960003806 metampicillin Drugs 0.000 description 1
- FZECHKJQHUVANE-MCYUEQNJSA-N metampicillin Chemical compound C1([C@@H](N=C)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 FZECHKJQHUVANE-MCYUEQNJSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- LULXBAGMGMJJRW-UHFFFAOYSA-N n,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)CC(=O)N[Si](C)(C)C LULXBAGMGMJJRW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- GNWXVOQHLPBSSR-UHFFFAOYSA-N oxolane;toluene Chemical compound C1CCOC1.CC1=CC=CC=C1 GNWXVOQHLPBSSR-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229950004791 pirbenicillin Drugs 0.000 description 1
- ICZHJFWIOPYQCA-UHFFFAOYSA-N pirkle's alcohol Chemical compound C1=CC=C2C(C(O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 ICZHJFWIOPYQCA-UHFFFAOYSA-N 0.000 description 1
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 1
- 229960003342 pivampicillin Drugs 0.000 description 1
- 108010074858 plaferon Proteins 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- HOCWPKXKMNXINF-XQERAMJGSA-N propicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(CC)OC1=CC=CC=C1 HOCWPKXKMNXINF-XQERAMJGSA-N 0.000 description 1
- 229960003672 propicillin Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 229960004932 sulbenicillin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002780 talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- GMRIOAVKKGNMMV-UHFFFAOYSA-N tetrabutylazanium;azide Chemical compound [N-]=[N+]=[N-].CCCC[N+](CCCC)(CCCC)CCCC GMRIOAVKKGNMMV-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- This invention relates to novel ⁇ -lactam containing compounds, their preparation and their use, and in particular to a novel class of clavams. These compounds have antibacterial and ⁇ -lactamase inhibitory properties, and therefore are of use in the treatment of bacterial infection either alone or in a synergistic composition with other ⁇ -lactam antibacterial agents, such as penicillins and cephalosporins.
- Clavulanic acid has the structure:
- the present invention provides certain 3-carboxyclavam derivatives having a propylidene moiety at the 2-position of the clavam nucleus.
- the present invention comprises compounds of the formula (II):
- R is hydrogen or a hydrocarbon group and where X is hydroxy, substituted hydroxy, mercapto, substituted mercapto; azido, cyano, halo, isothiocyanato, substituted amino or X represents the residue of a carbon nucleophile or is an activated aryl or heteroaryl group.
- Suitable substituted hydroxy groups for X include etherified and acylated hydroxy and suitable substituted mercapto groups include etherified and acylated mercapto.
- Suitable substituted amino groups for X include alkylated or acylated amino.
- hydrocarbon' includes groups having up to 18 carbon atoms, suitably up to 10 carbon atoms, conveniently up to 6 carbon atoms. Suitable hydrocarbon groups include C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1 _ 6 )-alkyl, aryl, and aryl (C 1-6 )alkyl .
- 'aryl' includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, C 1-6 alkyl, phenyl, C 1-6 alkoxy, halo(C 1-6 ) alkyl, hydroxy, amino, nitro, carboxy, C 1-6 alkoxycarbonyl, C 1-6 alkoxycarbonyl-(C 1-6 )-alkyl C 1-6 alkylcarbonyloxy, or C 1-6 alkylcarbonyl groups.
- X is hydroxy or substituted hydroxy.
- substituted hydroxy groups include -OR 1 , -OCOR 1 , -OCSR 1 , -OCO 2 R 1 , -OCS 2 R 1 , OCOSR 1 , -OCSOR 1 , -OSO 3 H, -OPO 3 H, -OSO 2 R 1 and -OCONR 2 R 3 wherein R 1 is a substituted or unsubstituted hydrocarbon group of 1 to 20 carbon atoms; and R 2 and R 3 are each independently hydrogen or substituted or unsubstituted hydrocarbon groups of 1 to 20 carbon atoms.
- R 1 is C 1-10 alkyl, C 2-10 alkenyl, aryl (C 1-6 ) alkyl, heterocyclyl (C 1-6 ) alkyl, aryl (C 2-6 ) alkenyl, heteroaryl (C 1-6 ) alkyl, C 3-8 cycloalkyl, aryl, heteroaryl, heterocyclyl or C 3-8 cycloalkyl (C 1-6 ) alkyl, any of such groups being optionally substituted.
- Suitable optional substituents for the group R 1 include C 1-6 alkyl, amino, C 1 -6 alkanoylamino, mono- and di- (C 1-6 ) alkylamino, hydroxy, C 1-6 alkoxy, mercapto, C 1-6 alkylthio, heteroarylthio, arylthio. oxo, sulphamoyl, carbamoyl, amidino, guanidino, nitro, chloro, bromo, fluoro, carboxy and salts and esters thereof, C 1-6 alkanoyloxy, arylcarbonyl and heteroarylcarbonyl.
- R 2 and R 3 are hydrogen or C 1-6 alkyl.
- X is C 1-6 alkoxy or benzyloxy optionally substituted by one, two or three halogen atoms, cyano, azido, hydroxy, C 1-6 alkoxy, C 2-6 alkanoyloxy, C 1-4 alkylthio, aryloxy such as phenoxy, amino, C 1-6 alkanoylamino, carboxy or esterified carboxy.
- X is methoxy
- X is C 1-6 alkanoyloxy such as acetoxy, C 1-6 alkyl sulphonyloxy such as methanesulphonyloxy or arylsulphonyloxy such as p-toluenesulphonyloxy, or C 1-6 alkylcarbamoyloxy such as methylcarbamoyloxy.
- X is mercapto or substituted mercapto.
- substituted mercapto groups include -SCOR 4 , -S-R 4 , -SCSR 4 , -SCO 2 R 4 , -SCS 2 R 4 , -SCOSR 4 , -SCSOR 4 , -SSO 2 R 4 , -SCONR 5 R 6 , -S(O)R 4 , -S(O) 2 R 4 and -S-SR 4 , wherein R 4 , R 5 and R 6 are independently substituted or unsubstituted hydrocarbon groups of 1 to 20 carbon atoms.
- substituents for R 4 , R 5 and R 6 include those described hereinabove as being suitable as substituents for R 1 .
- R 4 is a C 1-10 alkyl, C 2-10 alkenyl, aryl (C 1-6 ) alkyl, heterocyclyl (C 1-6 ) alkyl, aryl, (C 2-6 ) alkenyl, C 3-8 cycloalkyl (C 1-6 ) alkyl.
- X is a group -S(O) n R 7 wherein n is zero, one or two, and R 7 is benzyl, C 1-6 alkyl, C 2-6 alkenyl, aryl or heteroaryl, any of such groups R 7 being optionally substituted by one, two or three halogen atoms, azido, hydroxy, C 1-6 alkoxy, C 2-6 alkanoyloxy, C 1-4 alkylthio, aryloxy such as phenoxy, amino, C 1-6 alkanoylamino, carboxy or esterified carboxy.
- X is S(O) n R 7 wherein n is zero or two, and R 7 is C 1-6 alkyl such as methyl, benzyl, phenyl or tetrazolyl.
- X is thiophenyl
- X is substituted amino.
- substituted amino groups include -NHR 10 , -NR 10 R 11 , -NR 10 R 11 R 12 , -NHCX 1 R 10 , -NHCX 1 ZR 10 , -NHSO 2 R 10 , -NHCX 1 NR 10 R 11 , -N(CX 1 R 12 )R 13 , -N(CX 1 R 12 )CZR 13 , -N(CX 1 R 12 )ZR 13 , -N(CX 1 ZR 12 )R 13 and -N(CX 1 ZR 12 )CX 1 ZR 13 wherein X 1 and Z are each oxygen or sulphur and R 10 , R 11 , R 12 and R 13 are independently substituted or unsubstituted hydrocarbon groups of 1 to 20 carbon atoms.
- R 10 - R 13 include those described hereinabove as being suitable as substituents for R 1 .
- the groups R 10 and R 11 may be joined to form a heterocyclic ring containing from three to ten carbon atoms and not more than four heteroatoms selected from oxygen, nitrogen and sulphur. More suitably R 10 , R 11 , R 12 and R 13 are independently selected from C 1-10 alkyl, C 2-10 alkenyl, aryl (C 1-6 ) alkyl, heterocyclyl (C 1-6 ) alkyl, aryl
- C 2-6 alkenyl, C 3-8 cycloalkyl (C 1-6 ) alkyl, heterocyclyl, heterocyclyl (C 1-6 ) alkyl, aryl, heteroaryl and heteroaryl (C 1-6 ) alkyl, any of such groups being optionally substituted.
- X is an amino group substituted by at least one acyl and/or acyloxy group.
- X is an acetylamino or an N-acetyl- N-acetoxy amino group.
- X is C 1-6 alkylamino such as methylamino, ethylamino, propylamino and butylamino, di-(C 1-6 ) alkylamino such as diethylamino, benzylamino, C 1-8 alkanoylamino such as acetamido, succinimido or phthalimide, any of such groups being optionally substituted by one, two or three halogen atoms, or by an azido, hydroxy, C 1-6 alkoxy, C 2-6 alkanoyloxy, C 1-4 alkylthio, aryloxy such as phenoxy, amino, C 1-6 alkanoylami no , carboxy or esteri f ied carboxy group .
- C 1-6 alkylamino such as methylamino, ethylamino, propylamino and butylamino
- di-(C 1-6 ) alkylamino such as diethylamino
- X is succinimido.
- X is C 1-6 alkylamino, benzylamino, C 1-6 alkanoylamino or di-(C 1-6 ) alkylamino.
- X is an aryl or heteroaryl group bonded to the adjacent -CHR group via a carbon atom, for example phenyl, furyl, pyrrolyl, thienyl and such ring systems fused to a benzene ring, any of such groups being optionally substituted.
- Other heteroaryl groups for X which can be bonded to the adjacent CHR group by a nitrogen include triazolyl, tetrazolyl and trioxoimidazolidinyl, optionally substituted with C 1-6 alkyl or C 1-6 alkoxycarbonyl.
- X is triazolyl
- X is the residue of a carbon nucleophile such as of the sub-formula -CR 14 R 15 R 16 wherein R 14 and R 15 are the same or different and at least one of them represents a group capable of producing a stabilised carbanion, such as an electron withdrawing group, and R 16 is hydrogen or a substituted or unsubstituted hydrocarbon group of 1 to 20 carbon atoms.
- R 14 and R 15 may be selected from groups -CX 1 R 10 and CX 1 ZR 10 as previously described.
- R 16 may be defined as for R 10 hereinabove.
- X is -CH(COOR 1 7 )COR 18 or -CH (COR 17 )COR 18 wherein R 17 and R 18 are independently selected from C 1-10 alkyl, C 3-8 cycloalkyl, aryl such as phenyl, aryl (C 1-6 ) alkyl such as benzyl, any of groups R 17 and R 18 being optionally substituted by one, two or three halogen atoms, C 1-6 alkoxy, C 2-6 alkanoyloxy, C 1-4 alkylthio, aryloxy such as phenoxy, C 1-6 alkanoylamino or esterified carboxy.
- X is -CH(COCH 3 ) 2 .
- X is azido or cyano.
- X is a halo moiety for example iodo, bromo or chloro.
- Compounds wherein X is azido or halo are of particular interest as useful chemical intermediates.
- X is iodo.
- the major use of the compounds of the formulae (II)-(IV) and salts and esters thereof is as pharmaceuticals and accordingly the salts and esters of the compounds of the formulae (II)-(IV) are preferably pharmaceutically acceptable.
- the compounds of this invention both pharmaceutically acceptable and non-pharmaceutically acceptable may be used as intermediates and also as antibacterial agents or ⁇ -lactamase inhibitors in non-pharmaceutical usage such as a disinfectant or paint additive.
- Suitable pharmaceutically acceptable salts of the compounds of formula (II)-(IV) include metal salts such as aluminium, alkali metal salts such as sodium and potassium, and alkaline earth metal salts such as calcium or magnesium; and ammonium and substituted ammonium salts, for example those with lower alkylamines such as triethylamine, cycloalkylamines such as bicyclohexylamine, 1-ephenamine, N-ethylpiperidine and N-benzyl- ⁇ -phenethylamine.
- metal salts such as aluminium, alkali metal salts such as sodium and potassium, and alkaline earth metal salts such as calcium or magnesium
- ammonium and substituted ammonium salts for example those with lower alkylamines such as triethylamine, cycloalkylamines such as bicyclohexylamine, 1-ephenamine, N-ethylpiperidine and N-benzyl- ⁇ -phenethylamine.
- Non-pharmaceutically acceptable salts for use as intermediates include the lithium and silver salts.
- Suitable esters of the compounds of the formulae (II)-(IV) include those cleavable by biological methods such as enzymatic hydrolysis, in vivo hydrolysis, and those cleavable by chemical methods such as hydrogenolysis, hydrolysis, electrolysis or photolysis.
- the carboxylic acid i s esteri i fied by a group of the sub-formula ( a) , (b ) , (c ) , (d ) , ( e ) or ( f ) are examples of the sub-formula ( a) , (b ) , (c ) , (d ) , ( e ) or ( f ) :
- a 1 is a hydrogen atom, C 1-6 alkanoyl or an C 1-5 alkyl group optionally substituted by C 1-7 alkoxy or C 1-7 carboxylic acyloxy, or an alkenyl or alkynyl group of up to 5 carbon atoms;
- a 2 is a hydrogen atom or a methyl group;
- a 3 is a phenyl group or a phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, C 1-3 alkyl or C 1-3 alkoxy group;
- a 4 is a hydrogen atom or a phenyl group or phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, C 1-3 alkyl or C 1-3 alkoxy group;
- a 5 is a hydrogen atom or a methyl group;
- a 6 is a C 1-4 alkyl, phenyl or C 1-4 alkoxy group or A 5 is joined to A
- Favourably A 1 is a hydrogen atom or a methyl, ethyl, vinyl or ethynyl group.
- Favourably A 2 is a hydrogen atom.
- Favourably R 3 is a phenyl, p-bromophenyl, p-methoxyphenyl or p-nitrophenyl group.
- Favourably A 4 is a hydrogen atom.
- Favourably A 6 is a methyl, t-butyl or ethoxy group or is joined to A 5 .
- Favourably A 7 is a methyl group.
- Preferred groups of the sub-formula (a) include the methyl, ethyl and acetonyl groups.
- Preferred groups of the sub-formula (b) include the benzyl and p-nitrobenzyl groups.
- Preferred groups of sub-formula (c) include the acetoxymethyl, pivaloyloxymethyl, ⁇ -ethoxycarbonyloxymethyl and phthalidyl groups.
- a preferred group of the sub-formula (d) is the methoxymethyl group.
- Preferred groups of the sub-formula (e) include the trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl groups and tri-isopropylsilyl.
- a preferred group of the sub-formula (f) is p-methoxycarbonylbenzyl .
- esterifying groups are the p-nitrobenzyl and phthalidyl groups.
- Pharmaceutically acceptable in vivo hydrolysable esters are those esters which hydrolyse in the human body to produce the parent acid or its salt. Such esters may be identified by administration to a test animal such as a rat or mouse by intravenous administration and thereafter examining the test animal's body fluids for the presence of the compound of the formulae (II)-(IV) or salt.
- Suitable esters of this type include those of sub-formula (c) as hereinbefore defined.
- esters include di(C 1-6 ) alkylamino C 1-6 alkyl esters such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl and diethylaminoethyl.
- Esters of the compounds of the formula (II)-(IV) such as those of the sub-formula (a)-(f) if desired, may be presented in the form of their acid addition salts if an amino group is present in group X.
- the acid used to form the salt will most suitably be pharmaceutically acceptable, but non-pharmaceutically acceptable acid addition salts are also envisaged, for example as intermediates in the preparation of the pharmaceutically acceptable salts by ion exchange.
- Suitable pharmaceutically acceptable acid addition salts include those of inorganic and organic acids, such as hydrochloric, phosphoric, sulphuric, methanesulphonic, toluenesulphonic, citric, malic, acetic, lactic, tartaric, propionic and succinic acid.
- the acid addition salt is provided as a solid and preferably as a crystalline solid.
- Compounds of this invention when in crystalline form may be solvated, for example hydrated.
- the present invention provides a process for producing a compound of formula II by reduction of a compound of formula V
- R is as defined above in relation to formula (II), R a is hydrogen or a carboxy blocking group, Y is tetrazolyl or triazolyl each of which may be optionally substituted and each of which is bonded to the oxazolidene ring via a nitrogen atom, or -O.CO.R b where R b is hydrogen, alkyl, alkenyl, arylalkyl, aryl, cycloalkyl or heterocyclyl, and Z is an oxygen or sulphur atom and thereafter if necessary i) converting a compound of formula II where X is hydroxy or mercapto to a compound of formula (II) wherein X is not hydroxy or mercapto; ii) removing any carboxy blocking group R a , iii) converting the product into a salt or ester.
- the reduction is effected by conventional methods preferably using one or more mild reducing agetns. Care must be taken not to reduce the CO 2 R a group at the same time.
- Z is oxygen
- Y when Y is tetrazolyl or triazolyl, suitable substituents are esterified or salified carboxy, optionally substituted C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, or aryl, azido, isocyano, cyano, nitro, bromo, chloro, or a group of the sub-formula -(CO) n -NR x RY wherein n is zero or one, R x is hydrogen or optionally substituted C 1-6 alkyl, C 1-6 alkanoyl, or arylcarbonyl, and R Y is hydrogen, C 1-6 alkyl or C 1-6 alkanoyl, or R x and R Y may be joined to form (with the nitrogen atom to which they are attached) an optionally substituted 4,5 or 6-membered ring.
- Preferred substituents are optionally substituted C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, or aryl; azido, isocyano, cyano, nitro, bromo, chloro, or a group of the sub-formula -NRxRY wherein R x is hydrogen or optionally substituted C 1-6 alkyl, C 1-6 alkanoyl, or arylcarbonyl, and R Y is hydrogen, C 1-6 alkyl or C 1-6 alkanoyl, or R x and R Y may be joined to form (with the nitrogen atom to which they are attached) an optionally substituted 4,5 or 6-membered ring.
- alkyl and alkenyl groupsor moieties have from 1 to 6 carbon atoms; aryl groups include those selected from phenyl; phenyl substituted in one or more positions in the ring by one or more of alkyl, alkenyl, alkoxy, halo such as chloro, alkyl substituted by halo such as trifluoromethyl, nitro, amino, mono- or di-alkylamino, carboxy, alkoxycarbonyl, acylamino and like substitutents ; naphthyl, quinolyl each of which may be optionally substituted as defined above in relation to 'phenyl'; and cycloalkyl and heterocyclyl groups have from 3 to 10 atoms selected from C, N, O and S such as pyrrolyl, furyl, thienyl and pyridyl.
- Y is tetrazolyl or triazolyl, each of which may be optionally substituted by C 1-6 alkyl, C 2-6 alkenyl, bromo or chloro, or -O.CO.R b where R b is hydrogen, C 1-6 alkyl, C 2-6 alkenyl or optionally substituted phenyl.
- R b is hydrogen, C 1-6 alkyl, C 2-6 alkenyl or optionally substituted phenyl.
- Y is 2-tetrazolyl, optionally 5-substituted by alkyl; triazolyl; or -O.CO.R b where R b is alkyl or aryl.
- Y is 2-tetrazolyl, optionally 5-substituted by C 1-4 alkyl; triazolyl; or -O.CO.R b where R b is C 1-4 alkyl or phenyl.
- R b is C 1-4 alkyl or phenyl.
- Preferred C 1-4 alkyl groups are methyl and ethyl. An especially preferred C 1-4 alkyl group is methyl.
- Suitable carboxy-protecting groups for the group -CO 2 R a in formula (V) include ester derivatives of the carboxylic acid.
- the derivative is preferably one which may readily be cleaved at a later stage of the reaction.
- Suitable ester-forming carboxy-protecting groups are those which may be removed undr conventional conditions.
- Such groups for R a include benzyl, p-methoxybenzyl, 2, 4, 6-trimethylbenzyl, 3, 5-di-t-butylbenzyl, 4-pyridylmethyl, allyl, diphenylmethyl, triphenymethyl, 2-benzyloxyphenyl, 4-methylthiophenyl, methoxymethyl, a silyl or a phosphorus-V-containing group, or methyl or ethyl, but especially benzyl.
- the free carboxylic acid or a salt thereof may be regenerated from any of the above esters by usual methods appropriate to the particular R a group; for example, by base-catalysed hydrolysis, by enzymically-catalysed hydrolysis or by hydrogenation.
- the reduction of the compound (V) to give compound (II) involves two steps, namely reduction of the moiety and removal of the group Y. These two steps may be performed in one reaction or seperately, depending on the nature of the groups involved. For example, when Y represents a group -O.CO.R b , the process is conveniently carried out in two stages, by initially reducing the compound (V), for example with zinc borohydride to give an allylic alcohol of formula (VI):
- the group Y may then be removed by further reduction, for example catalytic hydrogenation, preferably after protection of the alcohol group.
- the alcohol may be protected by silylation to form a protected derivative of formula (VI A):
- R9 is a hydrocarbon group as defined hereinbefore.
- Suitable silylating agents include halosilanes or silazanes, particularly trimethylchlorosilane, dimethyl-dichlorosilane or bis(trimethyl silyl) acetamide. This protected intermediate can then be reduced using standard reactions with conventional reducing agents for example hydrogen in the presence of palladium catalyst.
- the hydrogenation reaction is effected in a solvent inert under reaction conditions such as toluene, tetrahydrofuran, dioxan, ethanol or aqueous ethanol or mixtures thereof.
- the protecting group is subsequently cleaved after the hydrogenation to yield the free acid, ester or salt of formula (II).
- the reduction and removal of the Y group to produce a compound of formula II may be effected in one stage using an appropriate reducing agent such as zinc borohydride.
- This reaction normally takes place in a solvent inert under the reaction conditions such as toluene, dichloromethane, tetrahydrofuran or dioxan, or mixtures thereof, but especially tetrahydrofuran and toluene.
- the reaction is generally carried out at a depressed or non-elevated temperature, for example -80o to +30oC, and preferably at a depressed temperature, for example -20o to + 20oC, and conveniently at about 0oC.
- This process may produce isomers of formula II with both Z and E sterochemistry about the double bond.
- the two isomers can be separated using conventional methods and where required the E isomer can be converted to the Z isomer using ultra violet light.
- R a and Y are as defined above in relation to formula (V) .
- a compound of formula (VII) is subjected to ozonolysis to produce an intermediate compound of formula (VIII)
- R d , R e and R f are each independently C 1-6 alkyl, aryl or aryl (C 1-6 ) alkyl.
- R d , R e and R f are phenyl.
- R a is as defined in relation to formula (V) with
- R 19 and R 20 are each independently C 1-6 alkyl, aryl or aryl(C 1-6 )alkyl;
- k, 1 and m are each independently 0 or 1
- R 21 , R 22 and R 23 are each independently C 1-6 alkyl, aryl or aryl(C 1-6 )alkyl.
- Suitable compounds of formula (XIV) include those wherein R 19 and R 20 are each independently methyl, ethyl, propyl, butyl, phenyl or benzyl. It is generally convenient that R 19 and R 20 represent the same moiety. Particularly suitable compounds of the formula (XIV) include those wherein R 19 and R 20 each represent ethyl, t-butyl or isopropyl, but especially ethyl.
- Suitable compounds of formula (XV) include those wherein R 21 , R 22 and R 23 are each independently methyl, ethyl, n-propyl, n-butyl, benzyl, phenyl or methoxyphenyl. It is generally convenient that R 21 , R 22 and R 23 each represent the same moiety.
- Favoured compounds of formula (XV) include tri-arylphosphines and tri-alkylphosphites. Particularly suitable compounds of formula (XV) include triphenylphosphine, trimethylphosphite, triethylphosphite and tri-pmethoxyphenylphosphine, but especially triphenylphosphine.
- Compounds of formula VIIA can be derived by conventional methods from clavulanic acid of formula (I).
- the present invention also provides a process for the production of a compound of formula II wherein R is hydrogen by reduction of a compound of formula X
- R a is as defined hereinbefore in relation to formula (V); and thereafter if necessary
- a suitable method of reduction utilises a complex hydride such as a borohydride, for example lithium borohydride, sodium cyanoborohydride, di-isobutyl aluminium hydride; or a reagent such as aluminium tri-isopropoxide.
- a complex hydride such as a borohydride, for example lithium borohydride, sodium cyanoborohydride, di-isobutyl aluminium hydride; or a reagent such as aluminium tri-isopropoxide.
- Such reaction may be performed in an inert organic solvent such as a hydrocarbon, a chlorinated hydrocarbon or an ether, for example toluene, cyclohexane, diethyl ether, heptane, hexane, dichloromethane or tetrahydrofuran.
- the reaction may be performed at any non-extreme temperature for example -30oC to +60°C, more suitably 0oC to +30o
- R a is as defined hereinabove in relation to formula (V).
- a compound of formula (XI) is treated with a silylating agent.
- Suitable silylating agents include halosilanes or silazanes.
- the si lylated i ntermedi ate has the formu la
- R a and R9 are as defined hereinbefore in relation to formula (V) and (VI A) respectively.
- This intermediate is not stereospecific with respect to the double bond at the 3 carbon position in the side chain. It is then subjected to a peracid oxidation step to give a second intermediate of formula
- R h is a residue of carboxylic acid.
- Suitable peracids include peracetic acid and perbenzoic acid.
- the second intermediate is reacted with a tetra alkyl ammonium fluoride, for example tetraethyl ammonium fluoride dihydrate which produces a compound of formula XII
- R a is as defined hereinbefore in relation to formula V.
- This compound (XIII) is novel and forms part of the invention.
- the reduction reaction can be carried out by conventional methods.
- a suitable method of reduction utilizes a complex hydride such as borohydride.
- borohydride for example lithium borohydride, sodium or potassium borohydride, sodium cyanoborohydride, di-isobutyl aluminium hydride; or a reagent such as aluminium tri-isopropoxide.
- compounds wherein X is halo may be prepared by reaction with a halogenating agent such as a non-metallic halide for example phosphorus trichloride, phosphorus tribromide, thionyl chloride, thionyl bromide or the halogenating agent may be a hydrocarbonsulphonyl halide generally used in the presence of halide ions, for example an alkanesulphonyl halide such as methanesulphonylchloride or an arylsulphonyl halide such as p-toluenesulphonyl chloride; the source of halide ions may be lithium halide or an amine salt.
- a halogenating agent such as a non-metallic halide for example phosphorus trichloride, phosphorus tribromide, thionyl chloride, thionyl bromide or the halogenating agent may be a hydrocarbonsulphonyl hal
- a base is present such as pyridine, and the reaction is preferably performed at a depressed or ambient temperature for example -60oC to +20°C.
- the compounds of the formula (II) wherein X is iodo are most conveniently prepared by a halogen exchange reaction, reacting the corresponding chloro or bromo compound with a source of iodide ions such as lithium iodide or trimethylphosphi te methiodide.
- Etherification of -OH or -SH may be effected by the reaction of a diazoalkane in the presence of a Lewis acid catalyst for example boron trifluoride preferably at a depressed or ambient temperature in an inert solvent.
- Acylation of -OH or -SH may be effected by reaction with an acylating agent e.g. RCY-T or RSO 2 T wherein T is a leaving group displaceable by a nucleophile.
- T is halo such as chloro or bromo, or a sulphonyloxy moiety, for example C 1-6 alkyl- or aryl- sulphonyloxy such as a mesylate or tosylate, or T is a carboxylate moiety, for example a C 1-6 alkanoyloxy group optionally substituted by 1 to 3 halogen atoms, in particular acetoxy or is an arylcarbonyloxy for example benzoyloxy.
- halo such as chloro or bromo
- a sulphonyloxy moiety for example C 1-6 alkyl- or aryl- sulphonyloxy such as a mesylate or tosylate
- T is a carboxylate moiety, for example a C 1-6 alkanoyloxy group optionally substituted by 1 to 3 halogen atoms, in particular acetoxy or is an arylcarbonyloxy for example benzoyloxy.
- such reaction is performed in the presence of a base such as an alkali or alkaline earth metal salt, in particular lithium, sodium or potassium carbonates; or an organic base such as amine for example pyridine or a tertiary amine and in particular triethylamine.
- a base such as an alkali or alkaline earth metal salt, in particular lithium, sodium or potassium carbonates
- organic base such as amine for example pyridine or a tertiary amine and in particular triethylamine.
- Suitable solvents include chloroform, dichloromethane, tetrahydrofuran, dimethylformamide, dimethylsulphoxide and acetone.
- the acylation reaction is performed at a non-extreme temperature for example at an ambient or slightly depressed temperature, such as -20oC to +20°C.
- T is a hydroxy group or hydrocarbyloxy for example C 1-6 alkoxy or aryloxy such as phenoxy.
- T is hydroxy preferably
- Compounds of the formula (II) wherein X is azido may be prepared by the reaction of an azide with a compound of the formula (II) wherein X is a readily displaceable group such as a halogen atom (chlorine or bromine) or a sulphonyloxy group.
- the azide is suitably an alkali metal azide such as sodium azide or an organic azide such as tetramethylguanidinuim azide or tetrabutylammonium azide.
- the reaction is preferably performed in an inert polar organic solvent such as acetonitrile, dimethylsulphoxide, ethyl acetate, dichloromethane, acetone or tetrahydrofuran at a non-extreme temperature.
- an inert polar organic solvent such as acetonitrile, dimethylsulphoxide, ethyl acetate, dichloromethane, acetone or tetrahydrofuran at a non-extreme temperature.
- Azide derivatives can also be prepared by the reaction of a compound of formula (II) wherein X is OH with hydrazoic acid in the presence of a compound of formula (XIV) as hereinbefore defined:
- the reaction is suitably performed in an inert organic solvent such as tetrahydrofuran or benzene, at a non-extreme temperature such as -20°C to +100°C usually at -50°C to 50°C and conveniently at ' ambient temperature.
- an inert organic solvent such as tetrahydrofuran or benzene
- Compounds of the formula (II) wherein X is substituted amino may be prepared by the reaction of the corresponding primary amine, for example by alkylation and/or acylation.
- Primary amines can be produced by reduction of the corresponding nitro compound which is described in European patent publication No. 2319 or by reduction of the corresponding azido compound.
- acyl and acyloxy amines can be obtained directly from the nitro compound by reaction with an acyl anhydride and zinc in the presence of acetic acid.
- Alkylation of the primary amine may be effected by reaction with a compound RX' ' wherein X'' is a leaving group to form a secondary amine (-NHR).
- This secondary amine then may be reacted with another compound RX' ' (which may be the same or different as the first) to form a tertiary amine (-NR 2 ). and subsequently, if desired, a quaternary amine (-NR 3 +) may be prepared, wherein the substituent groups are the same or different.
- Suitable groups X' ' include halo such as iodo and bromo, or a sulphonate such as a C 1-6 alkyl- or aryl- sulphonate for example methanesulphonate or p-toluenesulphonate.
- alkylation reactions are conveniently performed in an inert organic solvent such as dimethylformamide, acetonitrile or dichloromethane, preferably in the presence of strong non-nucleophilic organic base at a non-extreme temperature such as -20oC to +50oC, preferably -10°C to +20°C and most conveniently between 0oC and ambient.
- Suitable organic bases include 1, 5-diazabicyclo [4.3.0]non-5-ene and 1,8-diazabicyclo [5.4.0] undecene .
- Secondary and tertiary amines also may be prepared by the reaction of a compound of the formula (II) wherein X is a good leaving group, such as tosyloxy with a secondary amine (RNHR o ) to form a tertiary amine.
- X is a good leaving group, such as tosyloxy
- RNHR o secondary amine
- One or both of the groups R and R o may then be removed, for example by hydrogenation to provide a secondary or primary amine.
- Acylation of the primary amine (-NH 2 ) may be effected by reaction with an acylating agent.
- Apt acylating agents include any N-acylating compound suitable for the performance of analogous reactions with 6-aminopenicillanic acid or 7-aminocephalosporanic acid or salts or esters thereof , for example an acid halide , an anhydride or mixed anhydride or other reactive derivative, such as that produced by the reaction of an acid with an enzyme or a condensation-promoting agent such as dicyclohexylcarbodi-imide.
- the acylating agent is of the formula RX' ' where X' ' is a displaceable group, for example halo, sulphonate, carboxylate.
- the acylating agent also may be a ketene or isocyanate or isothiocyanate or an activated imide.
- a base for example an inorganic base such as an alkali or alkaline earth metal salt, in particular lithium, sodium or potassium carbonates; or an organic base such as an amine for example triethylamine.
- the reaction is performed in an aprotic organic solvent such as dimethylformamide, acetonitrile, ethyl acetate, dimethyl sulphoxide; water may be added to aid solubility if necessary.
- the reaction is suitably performed at a non-extreme temperature, for example between -20oC and 40oC and preferably at ambient temperature.
- Acylation may be effected on the primary amine (-NH 2 ) once or twice to form the mono-acyl or di-acyl derivatives, in the di-acyl case the acyl groups may be the same or different.
- acylation may be effected on a secondary amine (-NHR) to form the N-alkyl-N-acyl derivative.
- Di-acyl derivatives wherein the two acyl groups are joined so as to form a heterocyclic ring are most conveniently prepared by the reaction of a compound of the formula (II) wherein X is OH with a compound of the formula: HNR A R B wherein R A and R B form the heterocyclylic ring system in the presence of an azodicarboxylate compound of the formula (XIV) and (XV) as hereinbefore defined.
- the reaction is suitably performed in an inert organic solvent such as tetrahydrofuran and benzene, at a non-extreme temperature such as -20°C to +100°C, usually at -50°C to 50°C and conveniently, at ambient temperature.
- Bis-acyl derivatives can be prepared under similar reaction conditions by the reaction of a compound of formula (II) wherein X is OH with an O-acyl hydroxamic acid derivative of formula R c CO.NH.O.CO R d wherein R c and R d are each independently C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkyl acyl or aryl, in the presence of a compound of formula (XIV) and (XV) as hereinbefore defined.
- the foregoing reaction may also be used to prepare di-acyl derivatives wherein the two acyl groups are not joined. If one of the two acyl groups are removable for example hydrogenolysable then a mono-acyl derivative may be formed.
- Such compounds include phenol, phenol substituted by one, two or three atoms or groups selected from hydroxy, halo, C 1-6 alkoxy, C 1-6 alkyl or C 3-8 cycloalkyl; furan optionally substituted by C 1-6 alkyl, thiophene optionally substituted by C 1-6 alkyl, pyrrole optionally substituted by C 1-6 alkyl, or any of the aforementioned ring systems fused to an optionally substituted benzene ring.
- a catalyst is employed which is one known to catalyst reactions known as Friedel-Crafts reactions.
- Suitable catalysts include aluminium trichloride, zinc chloride, zinc bromide, antimony pentachloride, ferric chloride, stannic chloride, boron trifluoride etherate and chemical equivalents thereof. Of these boron trifluoride etherate is preferred.
- the reaction is generally performed in the presence of an inert organic solvent, preferably a non-polar solvent such as a halogenated hydrocarbon for example chloroform, carbon tetrachloride or dichloromethane. Suitable the reaction is performed at a depressed or moderate temperature, i.e. between +50oC and -70°C, preferably between 0oC and -30oC. Preferably the reaction is performed under an inert atmosphere.
- Compounds of the formula (II) wherein X is the residue of a carbon nucleophile may be prepared from compounds of the formula (II) wherein X is a displaceable group by reaction with a carbon nucleophile.
- the displaceable group may be halo such as chloro, bromo or iodo or aryl- or C 1-6 alkyl- sulphonyloxy for example p-toluenesulphonyloxy or methanesulphonyloxy.
- Reaction is suitably performed in an aprotic organic solvent at a depressed or ambient temperature for example -70°C to +25oC, preferably at -20oC to 0oC.
- Suitable solvents include tetrahydrofuran, dimethylformamide or dimethyl- sulphoxide.
- the carbon nucleophile may be a compound R-H in which case a base is present, or the carbon nucleophile may be presented as a salt.
- the cation in such a salt is suitably a metal ion or an ammonium ion, for example sodium, potassium, thallium or a tetra- C 1-6 -alkyl ammonium cation.
- Suitable salts include both pharmaceutically acceptable and non-pharmaceutically acceptable salts, for example inorganic salts such as metal salts (silver and mercuric), or alkali metal salts (sodium and lithium) and tertiary amine salts.
- inorganic salts such as metal salts (silver and mercuric), or alkali metal salts (sodium and lithium) and tertiary amine salts.
- the present invention also provides a pharmaceutical composition which comprises a compound of this invention and a pharmaceutically acceptable carrier.
- compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of the infection in animals especially mammals including humans.
- compositions of this invention include tablets, capsules, creams, syrups, suspensions, solutions, reconstitutable powders and sterile forms suitable for injection or infusion.
- Such compositions may contain conventional pharmaceutically acceptable materials such as diluents, binders, colours, flavours, preservatives, disintegrant and the like in accordance with conventional pharmaceutical practice in the manner well understood by those skilled in the art of formulating antibiotics.
- the injectable solution of the compound of this invention may be made up in a sterile pyrogen-free liquid such as water, aqueous ethanol or the like.
- An alternative approach to administering the compounds of this invention is to utilise an injectable suspension.
- Such suspensions may be made up in sterile water; sterile saline or the like and may also contain suspending agents such as polyvinylpyrrolidone, lecithin or the like.
- suspending agents such as polyvinylpyrrolidone, lecithin or the like.
- the zwitterionic compounds of this invention should be in the form of fine particles.
- compositions of a compound of the invention are particularly suitable as high blood levels of the compound can occur after administration by injection or infusion.
- one preferred composition aspect of this invention comprises a compound of the invention in sterile form and most suitably in sterile crystalline form.
- Such compostions may be prepared in an acceptable oil suspending agent such as arachis oil or its equivalent.
- an acceptable oil suspending agent such as arachis oil or its equivalent.
- the compounds of this invention should be in the form of fine particles.
- Unit dose compositions comprising a compound of this invention adapted for oral administration form a further suitable composition aspect of this invention.
- Unit dose compositions comprising a compound of this invention adapted for topical administration are also presented by this invention.
- the compound of the formula may be present in the composition as sole therapeutic agent or it may be present together with other therapeutic agents such as, for example, a penicillin or cephalosporin.
- a penicillin or cephalosporin which shows instability to ⁇ -lactamases since the resulting composition shows enhanced effectiveness (synergy).
- Suitable penicillins, cephalosporins or other ⁇ -lactam antibiotics for inclusion in such synergistic compositions include not only those known to be highly susceptible to ⁇ -lactamases but also those which have a degree of intrinsic resistance to ⁇ -lactamases.
- Suitable penicillins for inclusion in the compositions of this invention include benzylpenicillin, phenoxymethylpenicillin, carbenicillin, azidocillin, propicillin, ampicillin, amoxycillin, epicillin, ticarcillin, cyclacillin, pirbenicillin, azlocillin, mezlocillin, sulbenicillin, pipericillin, and other well known penicillins including pro-drugs thereof such as their in vivo hydrolysable esters such as the acetoxymethyl, pivaloyloxymethyl, ⁇ -ethoxycarbonyloxyethyl or phthalidyl esters of ampicillin benzylpenicillin or amoxycillin, and aldehyde or ketone adducts of penicillins containing a 6- ⁇ -aminoacetamide side chain (such as hetacillin, metampicillin and analogous derivatives of amoxycillin) or ⁇ -esters of carbenicillin or ticarcillin such as
- Suitable cephalosporins for inclusion in the compositions of this invention include, for example, cefatrizine, cephaloridine, cephalothin, cefazolin, cephalexin, cephacetrile, cephapirin, cephamandole nafate, cephradine, 4-hydroxycephalexin, cefaparole, cephaloglycin, cefoperazone, and other well known cephalosporins or pro-drugs thereof.
- Such compounds are frequently used in the form of a salt of hydrate or the like.
- the composition will be adapted for parenteral administration.
- Such penicillins may be used as a pharmaceutically acceptable salt such as the sodium salt.
- the ampicillin or amoxycillin may be used in the form of fine particles of the zwitterionic form (generally as ampicillin trihydrate or amoxycillin trihydrate) for use in an injectable suspension, for example, in the manner hereinbefore described for a compound of this invention.
- the preferred penicillin for use in the synergistic composition is amoxycillin, for example as its sodium salt or trihydrate.
- a cephalosporin or penicillin When present together with a cephalosporin or penicillin, the ratio of a compound of the invention to the penicillin or cephalosporin agent may vary over a wide range of ratios, such as from 10:1 to 1:10, for example about 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5 or 1:6 (wt/wt, based on pure free antibiotic equivalent).
- the total quantity of a compound of the invention in any unit dosage form will normally be between 25 and 1000 mg and will usually be between 50 and 500 mg, for example about 62.5, 100, 125, 150, 200 or 250 mg.
- compositions of this invention may be used for the treatment of infections of inter alia, the respiratory tract, the urinary tract and soft tissues in humans.
- the penicillins or cephalosporin in the synergistic composition of this invention will normally be present at approximately the amount at which it is conventionally used which will usually be expected to be from about 62.5 to 3000 mg per dose, more usually about 125, 250, 500 or 1000 mg per dose.
- One particularly favoured composition of this invention will contain from 150 to 1000 mg of amoxycillin as the trihydrate or sodium salt and from 25 to 500 mg of a compound of this invention.
- composition of this invention will contain from 150 to 1000 mg of ampicillin or a pro-drug thereof and from 25 to 500 mg of a compound of this invention.
- this form of composition will contain ampicillin trihydrate, ampicillin anhydrate, sodium ampicillin, hetacillin, pivampicillin, hydrochloride, bacampicillin hydrochloride or talampicillin hydrochloride. Most suitably this form of the composition will contain a zwitterionic compound of the formula (II) when in crystalline form.
- the preceding composition will contain from 200 to 700 mg of the penicillin component. Most suitably the preceding composition will comprise from 50 to 250 mg of a zwitterionic compound of the formula (II) preferably in crystalline form.
- compositions may be adapted for oral or parenteral use except when containing an in vivo hydrolysable ester of ampicillin or amoxycillin in which case the compositions will not be adapted for parenteral administration.
- compositions of this invention will contain from 200 to 2000 mg of carbenicillin, ticarcillin or a pro-drug thereof and from 50 to 500 mg of a compound of this invention.
- this form of composition will contain di-sodium carbenicillin.
- this form of the composition will contain di-sodium ticarcillin.
- this form of the composition will contain from 75 to 250 mg of a zwitterionic compound of the formula (II) preferably in crystalline form.
- Such compositions containing di-salts of carbenicillin and ticarcillin will be adapted for parenteral administration.
- the present invention also provides a method of treating bacterial infections in animals, in particular humans or domestic mammals, which comprises the administration of a composition of this invention
- the infection treated will be due to a strain of Staphylococcus aureus, Klebsiella aerogenes, Escherichia coli , Proteus sp. , Bacteroides fragilis or the like.
- the organisms believed to be most readily treated by an antibacterially effective amount of a compound of this invention is Staphylococcus aureus.
- the other organisms named are more readily treated by using a synergistically effective amount of the compound of this invention and a penicillin or cephalosporin.
- the administration of the two components may take place separately but in general we prefer to use a composition containing both the synergist and the penicillin or cephalosporin.
- the indications for treatment include respiratory tract and urinary tract infections in humans.
- Preparation 1a The indications for treatment include respiratory tract and urinary tract infections in humans.
- Benzyl 2-(tetrazol-2-yl)-2-vinyl clavam-3-carboxylate (4.7 g) in ethyl acetate (about 100 ml) was cooled to -65oC and the solution saturated with ozone (pale blue colour).
- Triphenylphosphine (3.5 g) was added and the mixture allowed to warm to -10oC.
- Formylmethylene-triphenylphosphorane (8 g) was slurried with N,N-dimethylformamide (3 x 50 ml portions) , allowing to settle partially each time and then adding the supernatant (and some solid) to the ozonolysis product, the remaining insoluble solid was also added.
- the mixture was allowed to stir at -10°C to 0°C for 2.5 hours.
- the insoluble material was filtered off and washed with toluene (1.5 g recovered) .
- the filtrate was diluted with toluene (30. ml) and poured into water (200 ml) , slightly acidified (pH 5) and separated.
- the aqueous phase was washed with three further portions of toluene-ethyl acetate (70 ml, 2:5) ; the combined solvent layers were then washed with water (50 ml) and dried over Na 2 SO 4 .
- the tic then showed three KMnO 4 positive zones and triphenyl phosphine oxide. The fastest running zone was triphenyl phosphine.
- the solvent phase was collected and evaporated under reduced pressure to an oil, which was subjected to chromatography on silica gel using ethyl acetate-hexane (1:1) . A partial separation was obtained. The fractions containing, the. desired product were combined, evaporated and rechromatographed on silica gel using a reverse gradient: 3:2 ethyl acetate-hexane, graded to 1:1 ratio. The first eluted component was the double-bond E isomer, followed by the title compound (100 mg) with the Z-configuration which had spectral characteristics identical to the material prepared by reduction of the aldehyde of example 3 hereinafter.
- silyl ether (0.1 g) from Preparation 2d in redistilled tetrahydrofuran (15 ml) containing saturated sodium bicarbonate solution (0.25 ml) and 10% pallatised charcoal (25 mg) was hydrogenated at ambient temperature and pressure until tic showed the virtual absence of starting material.
- the reaction was filtered through a bed of silica to remove catalyst, and the filtrate diluted with water, adjusted to pH 3 by the addition of "Amberlite" IR 120 (H form) resin. After a few minutes the resin was removed by filtration and the filtrate adjusted to pH 7 with lithium hydroxide.
- n-pentane 60 ml was added to the reaction. After a further 30 minutes stirring was halted and when a bilayer had formed the n-pentane layer was decanted and evaporated to an oil. This oil was extracted with n-pentane (50 ml) which was filtered through magnesium sulphate and evaporated to give an oil.
- Benzyl Z-2-(3-oxopropylidene)clavam-3-carboxylate (0.2, 0.665 mmol) was dissolved in dry dimethoxyethane (10 ml) and placed under a slow stream of dry nitrogen before being cooled to -20°C.
- Sodium borohydride (0.011 g, 0.29 mmol) was added portionwise and after 5 mins. the reaction was diluted with ethyl acetate and washed with dilute hydrochloric acid, sodium hydrogen carbonate solution and brine (2 x) before being dried (MgSO 4 ) and evaporated to an oil, 0.1833 g.
- Benzyl E-2-(4-oxobutylidene)clavam-3-carboxylate (3.13 g, 9.94 mmol) was dissolved in dry redistilled tetrahydrofuran (30 ml) ; placed under a slow stream of dry nitrogen and cooled to -20°C.
- Triethylamine (1.52 ml, 10.9 mmol) and trimethylsilyl trifluoromethanesulphonate (1.98 ml, 10.9 mmol) were then added dropwise simultaneously, with vigorous stirring. After 20 minutes n-pentane (50 ml) was added and after a further 30 minutes stirring was halted.
- n-pentane was decanted, the residue was extracted again with n-pentane (30 ml) at room temperature. The n-pentane extractions were combined and evaporated to a colourless oil which was further extracted with n-pentane (25 ml) . Evaporation of the n-pentane afforded the title ester as a chromatographically labile colourless oil of high purity (>90%) in 32.5% yield as a mixture of enolether olef inic isomers . v max . ( f ilm) , 1 807 ,
- the title ester may be resolved into pairs of isomers by silica gel cromatography (toluene/ethyl acetate 7:1 as eluent) but with concomitant reduction in yield due to its relative instability towards silica-gel.
- v max. (film) 3500, 1804, 1748, 1730 and sh 1700 cm -1 .
- N.M.R. silica gel cromatography
- Benzyl E-2-(3-hydroxy-4-m-chlorobenzoyloxy-4-trimethylsilyloxybutylidene)clavam-3-carboxylate (1.65 g, 2.95 mmol) was dissolved in dry dimethoxyethane (15 ml) and placed under a stream of dry nitrogen. The reaction was cooled to -20°C and tetraethylamonium fluoride dihydrate (0.593 g, 3.2 mmol) was added portionwise. After 10 mins sodium borohydride (0.041 g, 1 mmol) was added.
- Lithium Z-2-(3-N-methylcarbatmoyloxypropylidene) clavam-3- carboxylate Lithium Z-2-(3-N-methylcarbatmoyloxypropylidene) clavam-3- carboxylate.
- the residual solid was crystallised from aqueous acetone to give a 3:1 mixture of lithium Z-2-(3-N-raethylcarbamoyloxypropylidene)clavam-3-carboxylate and E-2-(3-N-methylcarbamoyloxypropylidene)clavam-3-carboxylate as a solid in 68% yield.
- Benzyl E-2-(3-N-methylcarbamoyloxypropylidene)clavam-3-carboxylate (219 mg; 0.61mmol) was dissolved in dry redistilled tetrahydrofuran (30ml) and hydrogenolysed over 10% palladium on carbon (110mg) for 25 minutes. The catalyst was filtered off and the filtrate was diluted with water (25ml) and the solution neutralised with 1M lithium hydroxide.
- the reaction mixture was diluted with ethyl acetate and washed with saturated sodium hydrogen carbonate solution and with brine.
- the solution was dried (MgSO 4 ) and evaporated to a syrup which was chromatographed on silica gel using n-hexane/ethylacetate (2:1) as eluent.
- the first eluted material was the title ester 73.3mg, 69% yield based on consumed substrate.
- the second eluted material was the alcohol substrate, 51.8mg.
- Benzyl 2-(3-hydroxypropylidene)clavam-3-carboxylate (0.13 g; 0.429 mmol) was hydrogenated at room temperature in tetrahydrofuran (7 ml) over 10% palladium on barium sulphate (0.04 g) for 12 min. after which thin layer chromatography showed that all of the starting material had been consumed.
- the catalyst was filtered off and washed with tetrahydrofuran. An equal volume of water was added to the combined filtrates and the pH adjusted to 7.2 with potassium hydroxide.
- the less polar isomer from Preparation 16a (4.5 g) was dissolved in ethyl acetate (100 ml), cooled to -65°C and saturated with ozone. Argon was passed through the solution whilst it warmed to -30°C. A solution of triphenylphosphine (2.5 g) in ethyl acetate (15 ml) was added and the mixture allowed to warm to between -20° and 0°C. (T.l.c. was used to monitor the decomposition of oxidants, using a starch-iodide spray to visualize the zones). After about 40 mins .
- Benzyl 2-acetoxy-2-vinylclavam-3-carboxylate 14 g (more polar isomer) was dissolved in ethyl acetate (250 ml) and saturated with ozone at -65°C.
- a solution of triphenylphosphine 8 g in ethyl acetate (20 ml) was added and the mixture allowed to warm to -30°C (monitored by t.l.c). After a short time ( ⁇ 1/2 hr) , a solution + suspension of formylmethylenetriphenylphosphorane (25 g) in warm N,N-dimethyl ⁇ formamide (150 ml) wasi added in two portions.
- the mixture was maintained at between -30° and -5°C for about 1.5 hr, when the reaction appeared to be substantially complete (by t.l.c).
- the unreacted phosphorane was removed by filtration, the filtrate diluted with toluene (200 ml) and ice-water to a total of about 1 litre.
- the mixture was agitated gently and then separated.
- the aqueous phase was washed with toluene, the solvent layers combined, washed with water, dried over Na 2 SO 4 , evaporated and subjected to chromatography on silica gel using ethyl acetatehexane (2:3) as eluent.
- the aldehyde of Preparation 16e (6 g) was dissolved in 1,2-dimethoxyethane (100 ml) and dry tetrahydrofuran (50 ml). Sodium borohydride (free from lumps, 0.16 g) was added; after 1/2 hr t.l.c showed some unreacted aldehyde so a further 0.12 g of NaBH. was added. T.l.c. then showed the absence of starting material, so the solution was diluted with an equal volume of water and of toluene, titrated to pH 5 with 1M HCl solution (frothing) and then separated.
- Benzyl 2-(3-hydroxypropylidene)clavam-3-carboxylate (mixture of E and Z isomers, mainly Z) (200 mg) in dry tetrahydrofuran (12 ml) containing triphenylphosphine (200 mg) and succinimide (200 mg) was stirred and cooled to 0°C. Diethyl azodicarboxylate (0.2 ml) was added and the mixture was allowed to warm to ambient temperature during 1/2 hr. It was found by t.l.c. that the reaction was incomplete, so 200 mg portions of phosphine, azodicarboxylate and succinimide were added and the reaction mixture stirred overnight at ambient temperature.
- Example 17a The product of Example 17a (25 mg) in redistilled tetrahydrofuran (5 ml) was hydrogenated over 10% palladised charcoal (12 mg) at ambient temperature and pressure; about 2 cm 3 of hydrogen was absorbed.
- the catalyst was removed by filtration, the filtrate diluted with water, titrated to pH .6.8 with dilute lithium hydroxide solution and evaporated to dryness under reduced pressure. After desiccation in vacuo , the residue was triturated with acetone, filtered off, washed with a little acetone and dried in vacuo , to yield a white solid (10 mg) . P.m.r.
- Benzyl 2-vinyl-2-acetoxyclavam-3-carboxylate (less polar isomer) (4.65 g) in ethyl acetate (100 ml) was cooled to -65°C with stirring and saturated with ozone.
- the mixture was flushed with argon while the temperature was allowed to rise to -30°C, then triphenylphosphine (3.66 g) was added.
- the mixture was stirred at 0 to -20°C during 1 hr, then a suspension of acetylmethylene triphenylphosphorane (8.1 g) in N,N-dimethylfor-mamide (30 ml) was added.
- reaction mixture was diluted with toluene, washed with water, dried over MgSO 4 and evaporated to an oil.
- Excess benzyl bromide was extracted from the residue with hexane and the insoluble gum chromatographed on silica gel using 2:2:1 cyclohexane-hexane-ethyl acetate, fractions containing the desired product were combined and evaporated to yield 450 mg.
- the benzyl ester of Example 18 (340 mg) was dissolved in methyl isocyanate (5 ml) and stirred at ambient temperature for 7 days. The excess reagent was evaporated by passing dry air through, and then the residue was dried in vacua . The product was chromatographed on silica gel using 2:2:1 hexanecyclohexane-ethyl acetate to give the product as an oil (395 mg) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composé de formule (II) ou son sel ou son ester, dans laquelle R représente l'hydrogène ou un groupe hydrocarbure et X représente un hydroxy, un hydroxy substitué, un mercapto, un mercapto substitué, un azido, un cyano, un halo, un isothiocyanato, un amino substitué ou X représente le résidu d'un nucléophile de carbone ou un aryle activé ou un groupe hétéroaryle. Des procédés de préparation de ces composés et de compositions pharmaceutiques les contenant sont également décrits.Compound of formula (II) or its salt or its ester, in which R represents hydrogen or a hydrocarbon group and X represents hydroxy, substituted hydroxy, mercapto, substituted mercapto, azido, cyano, halo, an isothiocyanato, a substituted amino or X represents the residue of a carbon nucleophile or an activated aryl or a heteroaryl group. Methods of preparing these compounds and pharmaceutical compositions containing them are also described.
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB838304954A GB8304954D0 (en) | 1983-02-23 | 1983-02-23 | Antibacterial agents |
GB8304954 | 1983-02-23 | ||
GB838324961A GB8324961D0 (en) | 1983-09-17 | 1983-09-17 | Chemical intermediates |
GB8324961 | 1983-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0137794A1 true EP0137794A1 (en) | 1985-04-24 |
Family
ID=26285313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84900634A Withdrawn EP0137794A1 (en) | 1983-02-23 | 1984-02-08 | Clavam derivatives |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0137794A1 (en) |
WO (1) | WO1984003282A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1546569A (en) * | 1975-07-29 | 1979-05-23 | Beecham Group Ltd | 1-oxa-1-dethiapenicillins methods for their preparation and compositions containing them |
GB1593275A (en) * | 1976-10-22 | 1981-07-15 | Glaxo Lab Ltd | Clavam derivatives |
DE2861335D1 (en) * | 1977-11-29 | 1982-01-21 | Beecham Group Plc | Clavulanic acid derivatives, a process for their preparation and compositions containing them |
GB2045236A (en) * | 1979-03-26 | 1980-10-29 | Hoechst Uk Ltd | Oxapenem derivatives |
EP0080285A1 (en) * | 1981-11-25 | 1983-06-01 | Beecham Group Plc | Therapeutic compounds containing beta-lactams |
EP0080286A1 (en) * | 1981-11-25 | 1983-06-01 | Beecham Group Plc | Antibacterial compounds containing beta-lactams, processes for their preparation and their use |
-
1984
- 1984-02-08 EP EP84900634A patent/EP0137794A1/en not_active Withdrawn
- 1984-02-08 WO PCT/GB1984/000034 patent/WO1984003282A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO8403282A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1984003282A1 (en) | 1984-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ196902A (en) | 6-alkylidene penems and pharmaceutical compositions | |
US5644053A (en) | Penam derivatives | |
US4798828A (en) | Heterocyclic-methylene-penems | |
US6600035B1 (en) | 6-(substituted methylene) penems and intermediates | |
EP0120613A1 (en) | Penem derivatives and precursors | |
US4395418A (en) | Penem-3-carboxylic acid derivatives | |
CA1339450C (en) | Stable oxapenem-3-carboxylic acids | |
AU634876B2 (en) | Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them | |
EP0231244A1 (en) | 6-alkylidene penems | |
EP0362622B1 (en) | Use of stable oxapenem-3-carboxylic acids for the manufacture of beta-lactamase inhibiting medicaments | |
EP0055062B1 (en) | Compounds containing beta-lactams | |
EP0210065A1 (en) | 6-Alkylidene penems | |
EP0137794A1 (en) | Clavam derivatives | |
EP0170028A1 (en) | Antibacterial 7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene derivatives | |
EP0060077A1 (en) | Beta-lactam antibiotics, their preparation and use | |
US4426389A (en) | Derivatives of clavulanic acid, a process for their preparation and their use | |
US4242262A (en) | 9-Nitromethyldeoxyclavulanic acid derivatives preparation and compositions | |
EP0080286A1 (en) | Antibacterial compounds containing beta-lactams, processes for their preparation and their use | |
US4275067A (en) | Decarboxyclavulanic acid thio ethers, their preparation and use | |
EP0127636A1 (en) | Compounds containing beta-lactams | |
EP0105658A1 (en) | Beta-lactam compounds | |
EP0135521A1 (en) | Clavam derivatives | |
EP0007717A1 (en) | Clavulanic acid derivatives, a process for their preparation, their use, and pharmaceutical compositions containing them | |
JPS63188684A (en) | Production of 7-oxo-4-thia-1-azabicyclo(3. 2. 0)hept-2-ene derivative | |
GB2197865A (en) | Azetidinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19840925 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR GB LI NL |
|
17Q | First examination report despatched |
Effective date: 19870914 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19880126 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STIRLING, IRENE Inventor name: HARBRIDGE, JOHN, BARRY Inventor name: BRUTON, GORDON |